The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 7, 2003, Pages 3346-3353

  Park, Jin Woo ^a   Yeh, Michael W ^a   Wong, Mariwil G ^a   Lobo, Margaret ^a   Hyun, William C ^b   Duh, Quan Yang ^c   Clark, Orlo H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; ONCOPROTEIN; PROTEIN P53; RAF PROTEIN; RAF1 PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADENOMA, OXYPHILIC; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BENZOQUINONES; CARCINOMA, PAPILLARY; CELL DIVISION; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MUTATION; PROTO-ONCOGENE PROTEINS C-RAF; QUINONES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038637205     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-020340     Document Type: Article

References (50)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648
2. Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh Q-Y, Clark OH 2001 Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91:2335-2342
3. Becker J, Craig EA 1994 Heat-shock proteins as molecular chaperones. Eur J Biochem 219:11-23
4. Hartl FU 1996 Molecular chaperones in cellular protein folding. Nature 381:571-579
5. Helmbrecht K, Zeise E, Rensing L 2000 Chaperones in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif 33:341-365
6. Yano M, Naito Z, Tanaka S, Asano G 1996 Expression and roles of heat shock proteins in human breast cancer. Jpn J Cancer Res 87:908-915
7. Yano M, Naito Z, Yokoyama M, Shiraki Y, Ishiwata T, Inokuchi M, Asano G 1999 Expression of hsp90 and cyclin D1 in human breast cancer. Cancer Lett 137:45-51
8. Yufu Y, Nishimura J, Nawata H 1992 High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. Leukemia Res 16:597-605
9. Ferrarini M, Heltai S, Zocchi MR, Rugarli C 1992 Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 51:613-619
10. Magnuson NS, Beck T, Vahidi H, Hahn H, Smola U, Rapp UR 1994 The Raf-1 serine/threonine protein kinase. Semin Cancer Biol 5:247-253
11. Chavany C, Mimnaugh E, Miller P, Bitton R, Nguyen P, Trepel J, Whitesell L, Schnur R, Moyer J, Neckers L 1996 p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem 271:4974-4977
12. Blagosklonny MV, Toretsky J, Neckers L 1995 Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 11:933-939
13. Miller P, Schnur RC, Barbacci E, Moyer MP, Moyer JD 1994 Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185. Biochem Biophys Res Commun 201:1313-1319
14. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM 1994 Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91:8324-8328
15. Supko JG, Hickman RL, Grever MR, Malspeis L 1995 Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305-315
16. Goretzki PE, Frilling A, Simon D, Roeher HD 1990 Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res 118:48-63
17. Zielke A, Tezelman S, Jossart GH, Wong M, Siperstein AE, Duh Q-Y, Clark OH 1998 Establishment of a highly differentiated thyroid cancer cell line of Hürthle cell origin. Thyroid 8:475-483
18. Ambesi-Impiombato FS, Parks LA, Coon HG 1980 Culture of hormone-dependent functional epithelial cells from rat thyroids. Proc Natl Acad Sci USA 77:3455-3459
19. Mosmann T 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
20. Polosa R, Prosperini G, Leir SH, Holgate ST, Lackie PM, Davies DE 1999 Expression of c-erbB receptors and ligands in human bronchial mucosa. Am J Respir Cell Mol Biol 20:914-923
21. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN 1987 A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239-3245
22. Thompson EW, Reich R, Shima TB, Albini A, Graf J, Martin GR, Dickson RB, Lippman ME 1988 Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res 48:6764-6768
23. Jossart GH, Epstein HD, Shaver JK, Weier HU, Greulich KM, Tezelman S, Grossman RF, Siperstein AE, Duh Q-Y, Clark OH 1996 Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines. J Clin Endocrinol Metab 81:3498-3504
24. Neckers L, Schulte TW, Mimnaugh E 1999 Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 17:361-373
25. Conroy SE, Sasieni PD, Fentiman I, Latchman DS 1998 Autoantibodies to the 90kDa heat shock protein and poor survival in breast cancer patients [Letter]. Eur J Cancer 34:942-943
26. Trieb K, Gerth R, Holzer G, Grohs JG, Berger P, Kotz R 2000 Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy. Br J Cancer 82:85-87
27. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP 1997 Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 89:239-250
28. Bergerat A, de Massy B, Gadelle D, Varoutas PC, Nicolas A, Forterre P 1997 An atypical topoisomerase II from Archaea with implications for meiotic recombination. Nature 386:414-417
29. Grenert JP, Sullivan WP, Fadden P, Haystead TAJ, Clark J, Mimnaugh E, Krutzsch H, Ochel HJ, Schulte TW, Sausville E, Neckers LM, Toft DO 1997 The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 272:23843-23850
30. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH 1999 Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42:260-266
31. 1 arrest. Cancer Res 60:3940-3946
32. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA 2001 Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 61:4003-4009
33. Murakami Y, Mizuno S, Hori M, Uehara Y 1988 Reversal of transformed phenotypes by herbimycin A in src oncogene expressed rat fibroblasts. Cancer Res 48:1587-1590
34. Uehara Y, Fukazawa H, Murakami Y, Mizuno S 1989 Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds. Biochem Biophys Res Commun 163:803-809
35. Nishida E, Gotoh Y 1993 The MAP kinase cascade is essential for diverse signal transduction pathways. Trends Biochem Sci 18:128-131
36. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, Rapp UR 1994 The ins and outs of Raf kinases. Trends Biochem Sci 19:474-480
37. Hagemann C, Rapp UR 1999 Isotype-specific functions of Raf kinases. Exp Cell Res 253:34-46
38. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D 1996 Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 2:668-675
39. Khan SM, Oliver RH, Dauffenbach LM, Yeh J 2000 Depletion of Raf-1 protooncogene by geldanamycin causes apoptosis in human luteinized granulosa cells. Fertil Steril 74:359-365
40. Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM 1996 Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 16:5839-5845
41. Stancato LF, Silverstein AM, Owens-Grillo JK, Chow YH, Jove R, Pratt WB 1997 The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J Biol Chem 272:4013-4020
42. Miller P, DiOrio C, Moyer M, Schnur RC, Bruskin A, Cullen W, Moyer JD 1994 Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins. Cancer Res 54:2724-2730
43. Sakagami M, Morrison P, Welch WJ 1999 Benzoquinoid ansamycins (herbimycin A and geldanamycin) interfere with the maturation of growth factor receptor tyrosine kinases. Cell Stress Chaperones 4:19-28
44. Hölting T, Siperstein AE, Clark OH, Duh Q-Y 1995 Epidermal growth factor (EGF)- and transforming growth factor α-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur J Endocrinol 132:229-235
45. Akslen LA, Varhaug JE 1995 Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 76:1643-1654
46. van der Laan BF, Freeman JL, Asa SL 1995 Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 5:67-73
47. Supino-Rosin L, Yoshimura A, Yarden Y, Elazar Z, Neumann D 2000 Intracellular retention and degradation of the epidermal growth factor receptor, two distinct processes mediated by benzoquinone ansamycins. J Biol Chem 275:21850-21855
48. Agnew EB, Wilson RH, Grem JL, Neckers L, Bi D, Takimoto CH 2001 Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 755:237-243
49. Kuduk SD, Harris TC, Zheng FF, Sepp-Lorenzino L, Ouerfelli Q, Rosen N, Danishefsky SJ 2000 Synthesis and evaluation of geldanamycin-testosterone hybrids. Bioorgan Med Chem Lett 10:1303-1306
50. Mandler R, Wu C, Sausville EA, Roettinger AJ, Newman DJ, Ho DK, King CR, Yang D, Lippman ME, Landolfi NF, Dadachova E, Brechbiel MW, Waldmann TA 2000 Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst 92:1573-1581